Table 1.
Basic clinical characteristics of all subjects at baseline.
Table 2.
Results of Pearson correlations of vaspin with clinical and biomedical indices at baseline.
Figure 1.
Percentages of new occurrences of T2DM in control subjects with low or high vaspin and adiponectin levels at follow-up.
Red and black bars represent new onset diabetic patients and non-diabetic subjects in control group at follow-up, respectively. χ2 test was used to analyze the difference of percentage of new onset diabetic patients in sub-groups with low and high vaspin levels.
Table 3.
Results of multiple stepwise logistic regression analysis for risk factors for new onset of T2DM in control group at follow-up.
Figure 2.
Glucose levels in groups with low and high serum vaspin concentrations.
Gray and black bars represent diabetic patients with low and high vaspin levels, respectively. Fasting plasma glucose (FPG), 2-hour postprandial plasma glucose (2h-PG) and glycosylated haemoglobin A1c (HbA1c) were compared between those at baseline and follow-up in control and T2DM groups. Covariance analysis was used to analyze the differences between sub-groups.
Table 4.
Medicine treatment in T2DM group with low or high vaspin and adiponectin levels at baseline and follow-up.